Evommune, Inc. (EVMN): Cash & Equivalents

Annual figures by period end, from SEC filings.

$44.06M

As of 2025-12-31

$60.03M

As of 2026-06-30

2024-12-31 Cash & Equivalents (USD) 2025-12-31

Period ended	Cash & Equivalents	Change YoY	Source filing
2025-12-31	$44.06M	+171.1%	2026-03-05, Balance as of period end
2024-12-31	$16.25M	n/a	2026-03-05, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cash & Equivalents	Change YoY
Evommune, Inc. (EVMN)	2025-12-31	$44.06M	+171.1%
Tonix Pharmaceuticals Holding Corp. (TNXP)	2025-12-31	$207.64M	+110.2%
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	$2.13M	+53.1%
Pyxis Oncology, Inc. (PYXS)	2025-12-31	$15.42M	-20.8%
Prelude Therapeutics Inc (PRLD)	2025-12-31	$35.26M	+182.6%
Arbutus Biopharma Corp (ABUS)	2025-12-31	$18.01M	-50.4%
Opus Genetics, Inc. (IRD)	2025-12-31	$45.09M	+48.7%
Jaguar Health, Inc. (JAGX)	2025-12-31	$968.0K	-87.9%
Crescent Biopharma, Inc. (CBIO)	2025-12-31	$213.19M	+513.2%

Compare EVMN, TNXP, EMMA, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗